234 related articles for article (PubMed ID: 30733338)
1. A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils.
Saelices L; Nguyen BA; Chung K; Wang Y; Ortega A; Lee JH; Coelho T; Bijzet J; Benson MD; Eisenberg DS
J Biol Chem; 2019 Apr; 294(15):6130-6141. PubMed ID: 30733338
[TBL] [Abstract][Full Text] [Related]
2. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
3. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
4. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S
Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899
[TBL] [Abstract][Full Text] [Related]
5. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
6. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the stabilities of synthetic
Raimondi S; Mangione PP; Verona G; Canetti D; Nocerino P; Marchese L; Piccarducci R; Mondani V; Faravelli G; Taylor GW; Gillmore JD; Corazza A; Pepys MB; Giorgetti S; Bellotti V
J Biol Chem; 2020 Aug; 295(33):11379-11387. PubMed ID: 32571879
[TBL] [Abstract][Full Text] [Related]
8. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.
Schmidt M; Wiese S; Adak V; Engler J; Agarwal S; Fritz G; Westermark P; Zacharias M; Fändrich M
Nat Commun; 2019 Nov; 10(1):5008. PubMed ID: 31676763
[TBL] [Abstract][Full Text] [Related]
10. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of transthyretin aggregation and toxicity.
Gasperini RJ; Klaver DW; Hou X; Aguilar MI; Small DH
Subcell Biochem; 2012; 65():211-24. PubMed ID: 23225005
[TBL] [Abstract][Full Text] [Related]
12. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis.
Morfino P; Aimo A; Panichella G; Rapezzi C; Emdin M
Heart Fail Rev; 2022 Nov; 27(6):2187-2200. PubMed ID: 35386059
[TBL] [Abstract][Full Text] [Related]
13. Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis.
Steinebrei M; Gottwald J; Baur J; Röcken C; Hegenbart U; Schönland S; Schmidt M
Nat Commun; 2022 Oct; 13(1):6398. PubMed ID: 36302762
[TBL] [Abstract][Full Text] [Related]
14. Relationship between amyloid deposition and intracellular structural changes in familial amyloidotic polyneuropathy.
Misumi Y; Ueda M; Obayashi K; Jono H; Su Y; Yamashita T; Ohshima T; Ando Y; Uchino M
Hum Pathol; 2012 Jan; 43(1):96-104. PubMed ID: 21777941
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for transthyretin amyloid formation in vitreous body of the eye.
Iakovleva I; Hall M; Oelker M; Sandblad L; Anan I; Sauer-Eriksson AE
Nat Commun; 2021 Dec; 12(1):7141. PubMed ID: 34880242
[TBL] [Abstract][Full Text] [Related]
16. The inhibition of cellular toxicity of amyloid-β by dissociated transthyretin.
Cao Q; Anderson DH; Liang WY; Chou J; Saelices L
J Biol Chem; 2020 Oct; 295(41):14015-14024. PubMed ID: 32769117
[TBL] [Abstract][Full Text] [Related]
17. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol and Sphingomyelin Uniquely Alter the Rate of Transthyretin Aggregation and Decrease the Toxicity of Amyloid Fibrils.
Ali A; Zhaliazka K; Dou T; Holman AP; Kurouski D
J Phys Chem Lett; 2023 Dec; 14(49):10886-10893. PubMed ID: 38033106
[TBL] [Abstract][Full Text] [Related]
19. Transthyretin deposition in familial amyloidotic polyneuropathy.
Saraiva MJ; Magalhaes J; Ferreira N; Almeida MR
Curr Med Chem; 2012; 19(15):2304-11. PubMed ID: 22471982
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes.
Sartiani L; Bucciantini M; Spinelli V; Leri M; Natalello A; Nosi D; Maria Doglia S; Relini A; Penco A; Giorgetti S; Gerace E; Mannaioni G; Bellotti V; Rigacci S; Cerbai E; Stefani M
Biophys J; 2016 Nov; 111(9):2024-2038. PubMed ID: 27806283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
